- PR Newswire•15 hours ago
OTCQX: RHHBY) and the SMA Foundation (SMAF) initiated a Phase 2 study in pediatric and adult Type 2/3 SMA patients. The study, named SUNFISH, is a two-part study investigating the safety, tolerability and efficacy of RG7916, an oral small molecule survival motor neuron 2 (SMN2) splicing modifier. Initiation of the pivotal second part of the study is expected to begin in 2017 and will trigger a $20 million milestone payment to PTC from Roche.
- The Wall Street Journal•yesterday
Roche Holding said sales climbed in the third quarter thanks to strong growth for several of its cancer and immunotherapy drugs.
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||29.18 - 29.48|
|52wk Range||29.18 - 35.13|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.77|
|Avg Vol (3m)||990,121|
|Dividend & Yield||1.02 (3.46%)|